SITC 2020看CD47风云:康方生物二代产品AK117优势明显 低剂量即实现最大受体占位

格隆汇APP
Nov 12, 2020

一直被业内认为是继PD-1/PD-L1之后攻克癌症的重磅“希望”的CD47,2020年热度可谓不断提升。在近期召开的SITC会议上,国内CD47最快的三个产品,天境生物的TJC4、信达的IBI88和康方生物的AK117都发布了最新的研究进展。从报告显示的内容来看,一直低调推进研发的康方生物AK117研究结果给人带来惊喜。康方生物在SITC 2020发布了《一项评估下一代抗CD47单抗(AK117)...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10